Movatterモバイル変換

[0]ホーム

Jump to content

Naptumomab estafenatox

العربية

Edit links

From Wikipedia, the free encyclopedia

Pharmaceutical compound

Naptumomab estafenatox
Monoclonal antibody
Schematic image of naptumomab estafenatox. V_H,V_L: variable (antigen binding) domains of antibody fragment C_H1,C_L: constant domains of antibody fragment SAg: superantigen SEA/E-120
Type	Fab fragment
Source	Mouse
Target	5T4
Clinical data
ATC code	none
Identifiers
CAS Number	676258-98-3^N
ChemSpider	none
UNII	93T929W6LC
Chemical and physical data
Formula	C₃₂₅₅H₅₀₂₅N₈₅₅O₁₀₅₀S₁₈
Molar mass	73513.02 g·mol⁻¹
^NY (what is this?) (verify)

Naptumomab estafenatox (ABR-217620) is adrug being developed for the treatment of various types ofcancer likenon-small cell lung carcinoma^[1] andrenal cell carcinoma.^[2]

Mechanism of action

[edit]

Chemically, it is afusion protein consisting of theantigen-binding fragment (Fab) of amonoclonal antibody with thesuperantigenstaphylococcal enterotoxin A (SEA/E-120, "estafenatox").^[3] The Fab binds to5T4, anantigen expressed by various tumor cells, and the superantigen induces an immune response by activatingT lymphocytes.^[4]

References

[edit]

^Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, et al. (September 2009)."Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer".Journal of Clinical Oncology.27 (25):4116–23.doi:10.1200/JCO.2008.20.2515.PMC 2734423.PMID 19636016.
^Clinical trial numberNCT00420888 for "ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma" atClinicalTrials.gov
^"Naptumomabum estafenatoxum"(PDF).WHO Drug Information.20 (4): 291. 2006. Archived fromthe original(PDF) on 2011-02-01.
^Eisen T, Hedlund G, Forsberg G, Hawkins R (February 2014)."Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin".Current Oncology Reports.16 (2): 370.doi:10.1007/s11912-013-0370-0.PMC 3918406.PMID 24445502.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab (+hyaluronidase) Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§